Intangible Assets

ONCO appears to have limited intangible asset protection because the provided metrics show deeply negative ROIC and ROCE, which indicates it is not converting any proprietary advantage into durable economic returns versus peers.

The absence of disclosed 5-year margin and growth history in the provided data weakens evidence that ONCO has a differentiated brand, IP, or regulatory asset that sustains pricing power better than peers.

In oncology, durable intangible assets usually come from patented therapies, approved indications, or exclusive clinical data, but no filing-based evidence was provided here to show ONCO has peer-leading exclusivity.

Compared with stronger biotech peers that can point to approved products or late-stage protected assets, ONCO’s current return profile suggests any intangible advantage is either early, narrow, or not yet monetized.

Without clear evidence of protected assets that improve retention or pricing power over 5–10 years, ONCO’s intangible moat looks weak relative to peers.

Switching Costs

ONCO shows no evidence in the provided data of customer lock-in, workflow dependence, or contractual switching frictions that would make patients, providers, or payers materially dependent on its offerings versus peers.

The very low asset turnover and negative capital returns suggest the business is not benefiting from a sticky installed base that would normally support recurring usage and retention.

In healthcare and oncology, switching costs are strongest when a therapy is embedded in treatment protocols or companion diagnostics, but no filing evidence was provided to show ONCO has that kind of peer-leading stickiness.

Compared with peers that have approved therapies, reimbursement entrenchment, or physician familiarity, ONCO does not currently show measurable switching barriers that protect margins.

Because the available metrics do not indicate repeat purchase behavior or retention advantages, switching costs appear weak and not durable.

Network Effects

ONCO’s business model, as reflected by the provided metrics, does not show a platform structure where more users, data, or participants directly increase value for other users versus peers.

Negative returns and minimal asset productivity do not support the presence of a self-reinforcing ecosystem that would compound adoption over time.

In oncology, network effects can arise from data networks, trial ecosystems, or provider referral density, but no filing-based evidence was provided to show ONCO has a peer-differentiated network.

Compared with digital health or platform peers, ONCO lacks visible evidence of cross-side adoption loops that would create durable competitive advantage.

Without a demonstrable ecosystem that improves with scale, network effects remain negligible.

Cost Advantage

ONCO’s negative ROIC and ROCE indicate it is not operating with a cost structure that converts into superior unit economics versus peers.

The extremely low asset turnover suggests weak asset productivity, which is inconsistent with a structural cost advantage that would support better margins over time.

No filing evidence was provided showing manufacturing scale, lower trial costs, or procurement advantages that would let ONCO undercut peers while preserving returns.

Compared with larger oncology peers that can spread fixed R&D, commercialization, or manufacturing costs across broader revenue bases, ONCO does not appear to have a durable cost edge.

Because the current metrics do not show superior efficiency or margin resilience, cost advantage is weak.

Efficient Scale

ONCO does not appear to operate in a clearly protected niche where market size is naturally limited and a small number of firms can serve demand efficiently better than peers.

The provided metrics show no evidence of profitable scale economics, since negative capital returns imply the business is not yet capturing the benefits of efficient scale.

In oncology, efficient scale is strongest when a company controls a narrow indication, specialized manufacturing, or a constrained distribution channel, but no filing evidence was provided to support that for ONCO.

Compared with established peers that already have commercial infrastructure and approved product concentration, ONCO does not show signs of industry structure that would shield it from competition.

Absent evidence of a limited market with durable capacity discipline, efficient scale is weak.

Overall Score

ONCO’s moat appears weak versus peers because the provided metrics show deeply negative returns and poor asset productivity, while no filing-based evidence was provided for protected IP, switching costs, network effects, cost advantage, or efficient scale. In oncology, durable advantage usually requires approved, exclusive assets or embedded clinical adoption, and ONCO does not currently show peer-leading evidence of those structural supports.